Cartesian Therapeutics, Inc.

RNAC · Nasdaq · United States

Share price · RNAC

$6.30-2.90 (-31.52%) 3M

close as of 2026-11-18 · 24h delayed · vol 170K (1.2x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when RNAC's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 9 Nov 2026-6.8%
  2. 6 Nov 2026+11.1%
  3. 15 Jun 2026-9.6%
  4. 12 Jun 2026+18.0%

    Nothing announced by RNAC that day or the session before.

  5. 10 Jun 2026+8.5%
  6. 9 Jun 2026+16.9%
  7. 9 Mar 2026+31.7%
  8. 5 Mar 2026-12.6%
  9. 12 Jan 2026-11.3%
  10. 22 Dec 2025-6.9%

Share of unusual movement by asset

For each asset, the share of RNAC's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Descartes-08
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—1%
Other company news (earnings, financing, releases naming no asset)—24%
Sessions with no dated event—75%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
BCMA (B-cell maturation antigen)Cell therapy
Myasthenia GravisDermatomyositis

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Descartes-08Phase 2Systemic Lupus Erythematosus (SLE)
Est. primary completion 2026-12-01 · NCT06038474 · CT.gov ↗
What to watch
Descartes-08Phase 3Myasthaenia Gravis
Est. primary completion 2026-12-30 · NCT06799247 · CT.gov ↗
What to watch
2027 (2)
November 2027 (1)
Descartes-08Phase 2Antisynthetase Syndrome
Est. primary completion 2027-11 · NCT07391605 · CT.gov ↗
What to watch
December 2027 (1)
Descartes-08Phase 1/2Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV), Juvenile Myasthenia Gravis, Juvenile Dermatomyositis
Est. primary completion 2027-12 · NCT07089121 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$0$16M$125M$11M-$28M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0$20M$149M—-$21M operating cash flowreport ↗
2026-Q1$0$19M$120M$39M-$22M operating cash flowreport ↗
2025-Q3$0$14M$145M$36M-$16M operating cash flowreport ↗
2025-Q2$0$15M$162M—-$18M operating cash flowreport ↗
2025-Q1$0.4M$15M$182M$18M-$23M operating cash flowreport ↗
2024-Q3$0$11M$221M$24M$14M operating cash flowreport ↗
2024-Q2$33M$13M$89M—-$14M operating cash flowreport ↗
2024-Q1$5.8M$9.7M$105M$57M-$16M operating cash flowreport ↗
2023-Q3$6.5M$13M$81M+ $0 short-term inv.$9.0M-$9.2M operating cash flowreport ↗
2023-Q2$5.3M$18M$115M+ $0 short-term inv.$11M-$9.9M operating cash flowreport ↗
2023-Q1$5.9M$19M$128M+ $0 short-term inv.$22M-$8.8M operating cash flowreport ↗
2022-Q3$21M$17M$114M+ $34M short-term inv.$7.9M$4.3M operating cash flowreport ↗
2022-Q2$39M$19M$139M+ $4.0M short-term inv.—-$12M operating cash flowreport ↗
2022-Q1$34M$18M$115M+ $4.0M short-term inv.—-$12M operating cash flowreport ↗
2021-Q3$24M$21M$116M+ $24M short-term inv.$18M-$11M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0.4M$58M$127M$33M-$74M operating cash flowreport ↗

Cartesian Therapeutics reported revenue of $0.4M, down 99.0% YoY, with R&D spend of $58.03M, up 28.6% YoY. The company held $126.87M in cash and equivalents and recorded a net loss of $130.3M, with a quarterly net burn of $130.3M.

The company noted its cash position is expected to fund operations into mid-2027, including completion of the Phase 3 AURORA trial of Descartes-08 in myasthenia gravis. Enrollment in AURORA continues, the Phase 2 TRITON trial in myositis is expected to initiate in 1H26, and the Phase 1/2 HELIOS pediatric trial is actively enrolling. Cartesian also highlighted recent Nature Medicine publications on Descartes-08 and board of directors appointments.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$38M$45M$214M$19M-$24M operating cash flowreport ↗
2023-FY$26M$72M$78M+ $0 short-term inv.$55M-$51M operating cash flowreport ↗
2022-FY$111M$72M$108M+ $28M short-term inv.—-$32M operating cash flowreport ↗
2021-FY$85M$69M$115M+ $14M short-term inv.$6.4M-$60M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 1 purchase ($206K), 3 sales ($259K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-04-02Kalayoglu Murat · 10% ownerOption exercise758,001——Form 4
2026-04-02Hoge Elizabeth; Seven One Eight Three Four Irrevocable Trust · 10% owner; 10% ownerOption exercise758,001——Form 4
2026-04-02Kalayoglu Murat · 10% ownerOption exercise (derivative)22,740.03——Form 4
2026-04-02Hoge Elizabeth; Seven One Eight Three Four Irrevocable Trust · 10% owner; 10% ownerOption exercise (derivative)22,740.03——Form 4
2026-03-13Singer Michael · directorGift6,555——Form 4
2026-01-06Davis Blaine · Chief Financial OfficerOpen-market sale10,591$6.82$72KForm 4
2026-01-06Miljkovic Milos · Chief Medical OfficerOpen-market sale3,573$6.82$24KForm 4
2026-01-06Brunn Carsten · director, President and CEOOpen-market sale23,766$6.82$162KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 83 reporting institutions held 7.2M shares ($43.7M, 23.4% of shares outstanding).

#InstitutionSharesValue
1Squarepoint Ops LLC2,238,486$13.8M
2FMR LLC799,743$4.9M
3BlackRock, Inc.599,108$3.7M
4VANGUARD CAPITAL MANAGEMENT LLC407,597$2.5M
5683 Capital Management, LLC330,000$2.0M
6MILLENNIUM MANAGEMENT LLC284,317$1.7M
7GEODE CAPITAL MANAGEMENT, LLC263,694$1.6M
8MARSHALL WACE, LLP251,115$1.5M
9Erste Asset Management GmbH221,705$1.3M
10STATE STREET CORP200,337$1.2M
11Privium Fund Management B.V.179,114$1.1M
12TWO SIGMA INVESTMENTS, LP167,313$1.0M
13UBS Group AG136,840$842K
14CITADEL ADVISORS LLC110,128$677K
15JACOBS LEVY EQUITY MANAGEMENT, INC101,534$624K